


Why Invest in NeoStem?

NeoStem is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease.

Our business includes the development of novel proprietary cell therapy products, as well as a revenue-generating contract development and manufacturing service business that we leverage for the development of our therapeutics while providing service to other companies in the cell therapy industry.

Name: NeoStem, Inc.
 Industry: Cell Therapy
 Stock Price: \$5.26
 52-Week Range: \$4.56 - \$8.29
 Shares Outstanding: 35 million
 Market Cap: \$186 million

Figures as of October 15, 2014, Shares Outstanding as of September 30, 2014.



Company Profile

NASDAQ: NBS

Our Development Pipeline: NeoStem has a multi-pronged research and clinical development strategy that targets multiple therapeutic platforms

Targeted Cancer Immunotherapy Program

- Recently expanded pipeline into cancer immunotherapies through acquisition of California Stem Cell, Inc.
- Developing therapies using reprogrammed dendritic cells to attack cancer initiating (stem) cells
- Expect to begin patient enrollment in Phase 3 Intus clinical trial for **melanoma** in 1Q 2015 (Special Protocol Assessment, Fast Track designation, and Orphan Drug designation)

Ischemic Repair Program

- Developing NBS10 (also referred to as AMR-001) to treat damaged heart muscle following a **heart attack**
- Release of data from PreSERVE AMI Phase 2 clinical trial expected November 17, 2014 at American Heart Association Scientific Sessions in Chicago, Illinois


Immune Modulation Program

- Developing Treg therapy to restore immune balance by enhancing Treg cell number and function
- Collaborating with UCSF and Dr. Jeffrey Bluestone, leading Treg expert
- Initiating Treg trials for **type 1 diabetes** (Phase 2), planned for 1H 2015, and **steroid resistant asthma** (Phase 1), planned for 4Q 2015*

Tissue Regeneration Program

- Exploring macular degeneration, the treatment of chronic wounds, and dermatological program
- Furthering research through \$4.5 million in cell therapy grants awarded to date (including DoD and NIH)

**Subject to review and approval of the protocols by the appropriate regulatory authorities.*



Our CDMO: Providing in-house development capabilities and driving growth in revenues through product and service expansion for clients

Progenitor Cell Therapy (PCT) an internationally recognized CDMO

- Advancing initiatives in Engineering & Innovation Center to lower cost of goods and improve robustness and efficiency of commercial production
- Expanding manufacturing capabilities domestically and internationally



Contact

Dr. Robin L. Smith

Chairman and Chief Executive Officer

212.584.4174 rsmith@neostem.com

420 Lexington Avenue, Suite 350, New York, NY 10170
 www.neostem.com

This material contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date hereof, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the development of the Company's cell therapeutics and the future of the cell therapeutics industry. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors including those described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (www.sec.gov) on March 13, 2014 and in the Current Report on Form 8-K filed on May 8, 2014. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

Management Highlights



Robin Smith, MD, MBA – Chief Executive Officer

- Led NeoStem since 2006, completed 6 acquisitions and 1 divestiture; extensive experience in executive & board level capacities for medical enterprises and healthcare-based entities



Robert Dickey IV – Chief Financial Officer

- 15+ years management experience at life science companies, including cell therapy experience as CFO of StemCyte, following a career as an investment banker at Lehman Brothers



Douglas W. Losordo, MD – Chief Medical Officer

- Leader in cell therapy research and renowned cardiologist; obtained over \$35 million in NIH funding during career-long efforts to develop novel therapeutics



Andrew L. Pecora, MD – Chief Visionary Officer

- Chief Innovations Officer at John Theurer Cancer Center at Hackensack University Medical Center; Co-founder of PCT; significant experience in design and conduct of clinical trials



Robert A. Preti, PhD – Chief Scientific Officer, President of PCT

- One of the country's leading authorities on cell engineering and co-founder of PCT; 10 years experience as Director of Hematopoietic Stem Cell Processing & Research Laboratory



Hans Keirstead, PhD – President, NeoStem Oncology

- 15+ years of experience; CEO of California Stem Cell prior to acquisition; Founder of Stem Cell Research Center, University of California, Irvine (UCI); Previously Professor, UCI; Previously CEO of Ability Biomedical



Stephen W. Potter, MBA – Executive Vice President

- Biotech and pharma experience at Osiris Therapeutics (approval of Prochymal[®], first-ever stem cell drug therapy), Genzyme, DuPont Pharmaceuticals, and Booz Allen & Hamilton



David Altarac, MD, MPA – Vice President, Regulatory Affairs

- Extensive experience in U.S. and global regulatory affairs, including strategy, operations, labeling and departmental leadership; 13 year tenure at Merck



Robert Dillman, MD – Vice President, Oncology

- Previously CMO of California Stem Cell prior to acquisition; Executive Medical Director of the Hoag Hospital Institute for Research and Education and Clinical Professor of Medicine at University of California, Irvine



Adel Nada, MD – Vice President, Immunotherapy

- Previously Senior Medical Director, Cardiovascular Cell Therapies at Baxter Healthcare; Previously led Clinical Pharmacology Medical Dept. at Abbott Laboratories



Catherine M. Vaczy, Esq. – General Counsel

- Senior business executive and counsel with 20+ years of leadership experience in the biotech industry; Previously senior executive at ImClone Systems (\$1 billion co-development deal in oncology forged with Bristol-Myers Squibb)